drugset / Trial / NCT04606433
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Phase 1
Active not recruiting
47 enrolled
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc. · collab
NaSequentialOpen-labelTreatment
Summary
An open, multicenter, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics, and antitumor activity of GNC-038 quad-specific antibody injection in relapsed or refractory non-Hodgkin's lymphoma, relapsed or refractory acute lymphoblastic leukemia, and refractory or metastatic solid tumors.
Timeline
- Start
- 2020-11-04
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GNC-038 | Monoclonal antibody | — | Intravenous |